Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.46 |
| ▸ | TLR7 | Q9NYK1 | 5/20 | 0.46 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.43 |
| ▸ | BRD4 | O60885 | 5/20 | 0.43 |
| ▸ | PPIA | P62937 | 1/20 | 0.40 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.39 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13195028 | 0.93 | KCNH2 (0.47) | TLR8TLR7BRD4PPIAPTGES | |
| SCHEMBL21920109 | 0.93 | BRD4 (0.44) | TLR8TLR7BRD4PPIAPTGES | |
| SCHEMBL15469765 | 0.87 | KCNH2 (0.45) | TLR8TLR7BRD4PPIAKCNH2 | |
| SCHEMBL15469717 | 0.86 | BRD4 (0.42) | BRD4PPIAPTGESALOX5CYP11B1 | |
| SCHEMBL17123640 | 0.85 | TLR8 (0.42) | TLR8TLR7BRD4KCNH2 | |
| SCHEMBL15469725 | 0.82 | TLR8 (0.37) | TLR8TLR7CDK1CDK5KCNH2 | |
| SCHEMBL17123643 | 0.82 | CYP1A2 (0.52) | TLR8TLR7BRD4PPIACYP11B1 | |
| SCHEMBL15469723 | 0.80 | TLR7 (0.36) | TLR8TLR7CDK1CDK5KCNH2 | |
| SCHEMBL20386594 | 0.80 | CYP1A2 (0.48) | TLR8TLR7BRD4PPIACYP11B1 | |
| SCHEMBL15469719 | 0.79 | TLR7 (0.44) | TLR8TLR7CDK1CDK5KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2021-01-28 | — | — | US | disclosed |
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2020-09-22 | — | — | US | disclosed |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2020-02-27 | — | — | US | disclosed |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-09-24 | — | — | US | disclosed |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2019-04-30 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2018-07-26 | — | — | US | disclosed |
| US-9790191-B2 | Substituted acylaminopyrimidines as inducers of alpha interferon production | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-17 | — | — | US | disclosed |
| US-9790191-B2 | Substituted acylaminopyrimidines as inducers of alpha interferon production | JANSSEN SCIENCES IRELAND UC (IE) | 2017-10-17 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2017-08-24 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-9422250-B2 | Pyrimidine derivatives for the treatment of viral infections | JANSSEN SCIENCES IRELAND UC (IE) | 2016-08-23 | — | — | US | disclosed |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | JANSSEN SCIENCES IRELAND UC (IE) | 2015-10-01 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | JANSSEN SCIENCES IRELAND UC (IE) | 2014-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10780089-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-20150274676-A1 | ACYLAMINOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS AND FURTHER DISEASES | DPYD, TYMP, ENTPD5 | TLR8 368/4885TLR7 171/4885CDK1 1051/4885 |
| US-20200061059-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-10420767-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-20140045849-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-10272085-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-11541050-B2 | Pyrimidine derivatives for the treatment of viral infections | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-20210023082-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-20180207155-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
| US-20170239245-A1 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF VIRAL INFECTIONS | TYMP, UMPS, HPRT1 | TLR8 1540/4885TLR7 1000/4885CDK1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.